Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BRAF |
| Variant | V600L |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | BRAF V600L (previously reported as V599L) lies within the activation segment of the protein kinase domain of the Braf protein (PMID: 15035987). V600L results in increased cell proliferation and cell viability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown. |
| Associated Drug Resistance | |
| Category Variants Paths |
BRAF mutant BRAF V600X BRAF V600L |
| Transcript | NM_004333.6 |
| gDNA | chr7:g.140753337C>G |
| cDNA | c.1798G>C |
| Protein | p.V600L |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001378468.1 | chr7:g.140753337C>G | c.1798G>C | p.V600L | RefSeq | GRCh38/hg38 |
| NM_004333.5 | chr7:g.140753337C>G | c.1798G>C | p.V600L | RefSeq | GRCh38/hg38 |
| NM_001354609.2 | chr7:g.140753337C>G | c.1798G>C | p.V600L | RefSeq | GRCh38/hg38 |
| NM_001354609.1 | chr7:g.140753337C>G | c.1798G>C | p.V600L | RefSeq | GRCh38/hg38 |
| NM_001378474.1 | chr7:g.140753337C>G | c.1798G>C | p.V600L | RefSeq | GRCh38/hg38 |
| NM_004333.6 | chr7:g.140753337C>G | c.1798G>C | p.V600L | RefSeq | GRCh38/hg38 |
| XM_005250045 | chr7:g.140753337C>G | c.1798G>C | p.V600L | RefSeq | GRCh38/hg38 |
| NM_004333 | chr7:g.140753337C>G | c.1798G>C | p.V600L | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600L | mucosal melanoma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in complete remission in a patient with unresectable hypopharyngeal mucosal melanoma harboring BRAF V600L (PMID: 35709404). | 35709404 |